TGFB1 polymorphisms and TGF‐β1 plasma levels identify gastric adenocarcinoma patients with lower survival rate and disseminated disease

Simple item page
dc.contributor.authorAlberto Gutierrez
dc.contributor.authorChristian Vaquero‐Yuste
dc.contributor.authorAdela López
dc.contributor.authorInmaculada Lasa
dc.contributor.authorRemedios Gómez
dc.contributor.authorJuárez Martín-Delgado, Ignacio
dc.contributor.authorMolanes López, Elisa María
dc.contributor.authorMartín Villa, José Manuel
dc.date.accessioned2024-01-10T17:45:15Z
dc.date.available2024-01-10T17:45:15Z
dc.date.issued2020-12-04
dc.description.abstract<jats:title>Abstract</jats:title><jats:p>TGF‐β1 is involved in tumour growth. Four TGFB1 SNPs and TGF‐β1 production by stimulated PBMC were determined in seventy‐eight gastric adenocarcinoma patients. In addition, TGF‐β1 levels were measured in the plasma of further thirty patients. rs1800471‐G/C genotype was prevalent in patients (20.7%) compared to controls (8.4%), as it also was the rs1800468 SNP‐G/A genotype in stage IV patients (20.7%) compared to stage I, II and III patients, combined (10.3%). Conversely, the T/T rs1800469 SNP‐T/T genotype was absent in the former group and present in 19.0% in the latter. Furthermore, the rs1800469‐C/rs1800470‐T (CT) haplotype was found in 15.0% of stage IV patients as compared to 3.0% of the remaining patients (3.0%) and also identifies patients with worse five‐year life expectancy (<jats:italic>P</jats:italic> = .03). TGF‐β1 synthesis by stimulated PBMCs was significantly lower in patients with the risk SNPs or haplotype, compared to the alternative genotype. Finally, TGF‐β1 plasma levels were lower in patients with worse life expectancy. Analysis of TGFB1 SNPs and measurement of plasma TGF‐β1 levels serves to identify patients at risk of developing a more aggressive disease.</jats:p>
dc.description.departmentDepto. de Inmunología, Oftalmología y ORL
dc.description.facultyFac. de Medicina
dc.description.refereedTRUE
dc.description.statuspub
dc.identifier.doi10.1111/jcmm.16131
dc.identifier.issn1582-1838
dc.identifier.issn1582-4934
dc.identifier.officialurlhttps://onlinelibrary.wiley.com/doi/10.1111/jcmm.16131
dc.identifier.urihttps://hdl.handle.net/20.500.14352/92364
dc.issue.number2
dc.journal.titleCellular and Molecular Life Sciences
dc.language.isoeng
dc.publisherWiley
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI18%2F00626/ES/HLA-G: CANCER GASTRICO Y SU EVOLUCION/
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.cdu612.017
dc.subject.ucmInmunología
dc.subject.unesco2412 Inmunología
dc.titleTGFB1 polymorphisms and TGF‐β1 plasma levels identify gastric adenocarcinoma patients with lower survival rate and disseminated disease
dc.typejournal article
dc.type.hasVersionAM
dc.volume.number25
dspace.entity.typePublication
relation.isAuthorOfPublication0894d58b-fe71-42aa-ad0a-19305823daa1
relation.isAuthorOfPublication29ce7a95-21d0-40ec-9fbe-c1062ff6d0a2
relation.isAuthorOfPublicationd6c35711-8ed5-412f-8345-8b8e3869353a
relation.isAuthorOfPublication.latestForDiscovery0894d58b-fe71-42aa-ad0a-19305823daa1
Download
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
JCMM-25-774.pdf
Size:
697.35 KB
Format:
Adobe Portable Document Format
downoload Download
Collections
Artículos